Jci_page_head_homepage_01 Jci_page_head_homepage_02
Masahisa Jinushi, Yukoh Nakazaki, Michael Dougan, Daniel R. Carrasco, Martin Mihm, Glenn Dranoff
Published in Volume 117, Issue 7
J Clin Invest. 2007; 117(7):1902–1913 doi:10.1172/JCI30966
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 8
MFG-E8 modulates the vaccination activity of irradiated, GM-CSF–secreting B16 cells.

(A) Wild-type C57BL/6 mice were vaccinated subcutaneously with 1 × 106 irradiated B16 cells as indicated and challenged on day 7 with 1 × 106 live B16 cells (8 mice per group). (B) C57BL/6 mice were injected with 1 × 106 live B16 cells, and the indicated vaccines were administered on days 0, 7, and 14 (8 mice per group). (C) Tumor-infiltrating lymphocytes were harvested from the B16 challenge sites of mice treated with the indicated vaccines and analyzed for FoxP3-expressing CD4+ T cells. Results are representative of 5 experiments. Numbers refer to the percentage of cells within an indicated gate. (D) Tumor-infiltrating lymphocytes were analyzed for FoxP3-expressing CD4+ T cells and CD8+ T cell activation. Similar results were obtained in 2 experiments. (E) Tumor-infiltrating lymphocytes were analyzed for TRP-2–specific IFN-γ production with an ELISPOT. E1A denotes a control H-2b restricted peptide derived from the adenoviral E1A gene product. SFC, spot forming cells. (F). Gross appearance of B16 challenge tumors in mice treated with the indicated vaccines (8 mice for B16/GM-CSF and B16/GM-CSF/MFG-E8 and 2 mice for B16/GM-CSF/RGE).